Skip to main content

Table 7 Risk of fracture associated with the use of bisphosphonates

From: Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand

  Adjusted OR (95 % CI) any fracture Adjusted OR (95 % CI) accidental fracture Adjusted OR (95 % CI) hip fracture
Use of bisphosphonate a
 No 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 Yes 4.12 (3.56–4.77) 4.21 (3.55–5.0) 5.20 (4.06–6.67)
Extent of disease a
 Localised    
 No bisphosphonate 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 Bisphosphonate 5.89 (2.81–12.38) 5.46 (2.38–12.50) 5.16 (0.61–43.55)
Locally advanced or Metastatic
 No bisphosphonate 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 Bisphosphonate 2.03 (1.42–2.90) 1.97 (1.17–3.33) 1.76 (0.79–3.91)
Unknown
 No bisphosphonate 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 Bisphosphonate 4.85 (4.11–5.73) 4.62 (3.83–5.56) 6.01 (4.61–7.83)
  1. OR odds ratio, CI confidence interval
  2. aAdjusted for age at diagnosis and ethnicity
  3. Bold indicate significant p-value (<0.5)